



RECEIVED  
CENTRAL FAX CENTER  
NOV 10 2011

ATTORNEYS AT LAW  
WASHINGTON HARBOUR  
3000 K STREET, N.W.  
SUITE 600  
WASHINGTON, D.C. 20007-5109  
202.672.5300  
202.672.5399  
WWW.FOLEY.COM

sbent@foley.com  
202.672.5404

## MEMORANDUM

CLIENT-MATTER NUMBER  
060348-0149

**TO:** Anoop Kumar Singh,  
Examiner U.S. Patent and Trademark Office  
Art Unit 1632

**FROM:** Stephen A. Bent,  
Reg. No. 29786 Foley & Lardner LLP

**DATE:** November 10, 2011

**RE:** *Request for Teleconference on Proposal for  
Claim Revisions in U.S. SN 10/588028*

---

Dear Dr. Singh,

Would you be willing to receive my call, at your convenience, to discuss a proposed revision, illustrated below, to the main claim of the captioned application?

If so, please let me know when and where I can reach you for this purpose.

Thanks for your attention to this request.

SAB

\*\*\*\*\*

*8. A targeted drug delivery method that comprises*

- (A) *providing a composition comprising (i) intact, bacterially derived minicells that are approximately 400 nm in diameter and that are loaded with a therapeutically significant concentration of a ~~small-molecule-drug~~ chemotherapeutic agent and (ii) bispecific ligands having specificity for a mammalian cell surface receptor and specificity for said minicells, wherein said composition is free of membrane blebs of 200 nm or less in size; and*
- (B) *contacting said composition with non-phagocytic mammalian cells, such that (i) said bispecific ligands cause said minicells to bind to said mammalian cells, (ii) said minicells are engulfed by said mammalian cells, and (iii) said ~~small-molecule-drug~~ chemotherapeutic agent is released into the cytoplasm of said mammalian cells.*